Date: Jan. 05, 2024

Your Name: W.K. Jacky Lam

Manuscript Title: Circulating tumour DNA analysis for early detection of lung cancer: A systematic

review

Manuscript number (if known): ATM-23-1572

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | Ti  | me frame: Since the initia   | l planning of the work  |
| 1 | All support for the                             | XNone  |   |
|   | present manuscript (e.g., funding, provision of |  |   |
|   | study materials, medical                        |  |   |
|   | writing, article processing                     |  |   |
|   | charges, etc.)  No time limit for this          |  |   |
|   | item.   |  |   |
|   |   |  |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                        | X_None   |   |
|   | any entity (if not indicated                    |  |   |
|   | in item #1 above).                              | V. N   |   |
| 3 | Royalties or licenses                           | XNone  |   |
|   |   |  |   |
|   |   |  |   |

| 4  | Consulting fees  | X None                               |   |
|----|--|--------------------------------------|---|
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone                                |   |
| 6  | Payment for expert testimony   | X_None                               |   |
| 7  | Support for attending meetings and/or travel   | XNone                                |   |
| 8  | Patents planned, issued or pending   |                                      | I have filed multiple patents on cell-free DNA analysis for cancer diagnostics. |
| 9  | Participation on a Data<br>Safety Monitoring Board<br>or Advisory Board                                      | Hong Kong Genome<br>Institute (HKGI) | I am a member of the Data Advisory Committee of the HKGI                        |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | DRA                                  | I am a Board member of DRA  |
| 11 | Stock or stock options   | Illumina, Inc                        | I hold equities in Illumina.  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | X_None                               |   |
| 13 | Other financial or non-<br>financial interests   | X_None                               |   |

# Please summarize the above conflict of interest in the following box:

I have filed multiple patents on cell-free DNA analyses for cancer diagnostics. I am a member of the Data Advisory Committee of the Hong Kong Genome Institute. I am a Board member of DRA and hold equities in Illumina.

Please place an "X" next to the following statement to indicate your agreement:

| _X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form. |
|--|
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |
|  |

Date: Jan. 05, 2024 Your Name: Jinyue Bai

Manuscript Title: Circulating tumour DNA analysis for early detection of lung cancer: A systematic

review

Manuscript number (if known): ATM-23-1572

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | Ti  | me frame: Since the initia   | l planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | X_None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | X_None   |   |
| 3 | Royalties or licenses   | XNone  |   |
|   |   |  |   |
|   |   |  |   |

| 4    | Consulting fees                           | X_None                  |                    |
|------|---|-------------------------|--------------------|
|      |   |                         |                    |
|      |   |                         |                    |
| 5    | Payment or honoraria for                  | X_None                  |                    |
|      | lectures, presentations,                  |                         |                    |
|      | speakers bureaus,                         |                         |                    |
|      | manuscript writing or                     |                         |                    |
| 6    | educational events Payment for expert     | V. None                 |                    |
| 6    | testimony                                 | X_None                  |                    |
|      | lestimony                                 |                         |                    |
| 7    | Support for attending                     | X None                  |                    |
| ,    | meetings and/or travel                    |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| 8    | Patents planned, issued                   | X_None                  |                    |
| 0    | or pending                                |                         |                    |
|      | or perioring                              |                         |                    |
|      | 5 5                                       | V N                     |                    |
| 9    | Participation on a Data                   | X_None                  |                    |
|      | Safety Monitoring Board or Advisory Board |                         |                    |
| 10   | Leadership or fiduciary                   | XNone                   |                    |
| '0   | role in other board,                      |                         |                    |
|      | society, committee or                     |                         |                    |
|      | advocacy group, paid or                   |                         |                    |
|      | unpaid                                    |                         |                    |
| 11   | Stock or stock options                    | X_None                  |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| 12   | Receipt of equipment,                     | X_None                  |                    |
|      | materials, drugs, medical                 |                         |                    |
|      | writing, gifts or other                   |                         |                    |
|      | services                                  |                         |                    |
| 13   | Other financial or non-                   | X_None                  |                    |
|      | financial interests                       |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| Plea | se summarize the above                    | conflict of interest in | the following box: |
|      |   |                         |                    |
| No   | one.                                      |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan. 06, 2024

Your Name: Mary-Jane L. Ma

Manuscript Title: Circulating tumour DNA analysis for early detection of lung cancer: A systematic

review

Manuscript number (if known): ATM-23-1572

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   | Ti   | me frame: Since the initia   | l planning of the work  |
| 1 | All support for the                            | XNone  |   |
|   | present manuscript (e.g.,                      |  |   |
|   | funding, provision of study materials, medical |  |   |
|   | writing, article processing                    |  |   |
|   | charges, etc.)                                 |  |   |
|   | No time limit for this                         |  |   |
|   | item.  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                       | XNone  |   |
|   | any entity (if not indicated                   |  |   |
|   | in item #1 above).                             |  |   |
| 3 | Royalties or licenses                          | X_None   |   |
|   |  |  |   |
|   |  |  |   |

| 4    | Consulting fees                           | X_None                  |                    |
|------|---|-------------------------|--------------------|
|      |   |                         |                    |
|      |   |                         |                    |
| 5    | Payment or honoraria for                  | X_None                  |                    |
|      | lectures, presentations,                  |                         |                    |
|      | speakers bureaus,                         |                         |                    |
|      | manuscript writing or                     |                         |                    |
| 6    | educational events Payment for expert     | V. None                 |                    |
| 6    | testimony                                 | X_None                  |                    |
|      | lestimony                                 |                         |                    |
| 7    | Support for attending                     | X None                  |                    |
| ,    | meetings and/or travel                    |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| 8    | Patents planned, issued                   | X_None                  |                    |
| 0    | or pending                                |                         |                    |
|      | or perioring                              |                         |                    |
|      | 5 5                                       | V N                     |                    |
| 9    | Participation on a Data                   | X_None                  |                    |
|      | Safety Monitoring Board or Advisory Board |                         |                    |
| 10   | Leadership or fiduciary                   | XNone                   |                    |
| '0   | role in other board,                      |                         |                    |
|      | society, committee or                     |                         |                    |
|      | advocacy group, paid or                   |                         |                    |
|      | unpaid                                    |                         |                    |
| 11   | Stock or stock options                    | X_None                  |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| 12   | Receipt of equipment,                     | X_None                  |                    |
|      | materials, drugs, medical                 |                         |                    |
|      | writing, gifts or other                   |                         |                    |
|      | services                                  |                         |                    |
| 13   | Other financial or non-                   | X_None                  |                    |
|      | financial interests                       |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| Plea | se summarize the above                    | conflict of interest in | the following box: |
|      |   |                         |                    |
| No   | one.                                      |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan. 06, 2024

Your Name: Y.T. Tommy Cheung

Manuscript Title: Circulating tumour DNA analysis for early detection of lung cancer: A systematic

review

Manuscript number (if known): ATM-23-1572

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
|   | Ti  | me frame: Since the initia   | l planning of the work  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item. | X_None   |   |
|   |   | Time frame: past   | 36 months   |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).  | X_None   |   |
| 3 | Royalties or licenses   | XNone  |   |
|   |   |  |   |
|   |   |  |   |

| 4    | Consulting fees                           | X_None                  |                    |
|------|---|-------------------------|--------------------|
|      |   |                         |                    |
|      |   |                         |                    |
| 5    | Payment or honoraria for                  | X_None                  |                    |
|      | lectures, presentations,                  |                         |                    |
|      | speakers bureaus,                         |                         |                    |
|      | manuscript writing or                     |                         |                    |
| 6    | educational events Payment for expert     | V. None                 |                    |
| 6    | testimony                                 | X_None                  |                    |
|      | lestimony                                 |                         |                    |
| 7    | Support for attending                     | X None                  |                    |
| ,    | meetings and/or travel                    |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| 8    | Patents planned, issued                   | X_None                  |                    |
| 0    | or pending                                |                         |                    |
|      | or perioring                              |                         |                    |
|      | 5 5                                       | V N                     |                    |
| 9    | Participation on a Data                   | X_None                  |                    |
|      | Safety Monitoring Board or Advisory Board |                         |                    |
| 10   | Leadership or fiduciary                   | XNone                   |                    |
| '0   | role in other board,                      |                         |                    |
|      | society, committee or                     |                         |                    |
|      | advocacy group, paid or                   |                         |                    |
|      | unpaid                                    |                         |                    |
| 11   | Stock or stock options                    | X_None                  |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| 12   | Receipt of equipment,                     | X_None                  |                    |
|      | materials, drugs, medical                 |                         |                    |
|      | writing, gifts or other                   |                         |                    |
|      | services                                  |                         |                    |
| 13   | Other financial or non-                   | X_None                  |                    |
|      | financial interests                       |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |
| Plea | se summarize the above                    | conflict of interest in | the following box: |
|      |   |                         |                    |
| No   | one.                                      |                         |                    |
|      |   |                         |                    |
|      |   |                         |                    |

Please place an "X" next to the following statement to indicate your agreement:

\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: Jan. 05, 2024

Your Name: Peiyong Jiang

Manuscript Title: Circulating tumour DNA analysis for early detection of lung cancer: A systematic

review

Manuscript number (if known): ATM-23-1572

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
|   | l I  | me frame: Since the initial  | planning of the work  |
| 1 | All support for the                            | XNone  |   |
|   | present manuscript (e.g.,                      |  |   |
|   | funding, provision of study materials, medical |  |   |
|   | writing, article processing                    |  |   |
|   | charges, etc.)                                 |  |   |
|   | No time limit for this                         |  |   |
|   | item.  |  |   |
|   |  |  |   |
|   |  | Time frame: past   | 36 months   |
| 2 | Grants or contracts from                       | X_None   |   |
|   | any entity (if not indicated                   |  |   |
|   | in item #1 above).                             |  |   |
| 3 | Royalties or licenses                          | KingMed Future,  |   |
|   |  | DRA, Take2, Illumina   |   |

|    |  | Insighta                                 |  |
|----|--|--|--|
| 4  | Consulting fees  | KingMed Future                           |  |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone                                    |  |
| 6  | Payment for expert testimony   | X_None                                   |  |
| 7  | Support for attending meetings and/or travel   | XNone                                    |  |
| 8  | Patents planned, issued or pending   | Various patents related to cell-free DNA |  |
| 9  | Participation on a Data<br>Safety Monitoring Board<br>or Advisory Board                                      | XNone                                    |  |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | Insighta, DRA, KMF,<br>and Take2         |  |
| 11 | Stock or stock options   | Illumina, KingMed<br>Future, Take2       |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services                    | XNone                                    |  |
| 13 | Other financial or non-<br>financial interests   | X_None                                   |  |

# Please summarize the above conflict of interest in the following box:

P.J. holds equities in Grail/Illumina, KingMed Future and Take2. P.J. is a consultant to KingMed Future and receives consulting fees. P.J. is Director of DRA, Take2, KingMed Future, and Insighta. P.J. filed various patents or patent applications related to cell–free DNA. Royalties are received from Illumina, Take2, DRA, and KingMed Future.

| Please place an "X" next to the following statement to indicate your agreement:  |  |  |
|--|--|--|
| _X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form. |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |